Double-hit signature with TP53 abnormalities predicts poor survival in patients with germinal center type diffuse large B-cell lymphoma treated with R-CHOP.

CONCLUSIONS: We propose a practical schema to utilize genomic variables to risk-stratify patients with GCB DLBCL. This schema provides a promising new approach to identify high-risk patients for new and innovative therapies.
PMID: 33414134 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - January 7, 2021 Category: Cancer & Oncology Authors: Song JY, Perry AM, Herrera AF, Chen L, Skrabek P, Nasr M, Ottesen R, Nikowitz J, Bedell V, Murata-Collins JL, Li Y, McCarthy C, Pillai RK, Wang J, Wu X, Popplewell L, Kwak LW, Nademanee A, Niland JC, Scott DW, Gong Q, Chan WC, Weisenburger D Tags: Clin Cancer Res Source Type: research